CURRICULUM VITÆ

Vincent Poitout, DVM, PhD

Professor of Medicine, University of Montréal

Canada Research Chair in Diabetes and Pancreatic Beta-Cell Function

Updated April 20, 2010

Office: CRCHUM Biotech Angus
2901, Rachel East
Suite 303
Montreal, QC H1W 4A4
Canada
Phone : (514) 890-8000 Ext. 23603
Fax : (514) 412-7661
E-mail: vincent.poitout@umontreal.ca
Website : www.poitoutlab.ca

Home address: 433 Lansdowne
Westmont, QC H3Y2V4
Canada
Phone: (514) 933-2043

Personal data: Birth date: January 10, 1965
Married, three children

Citizenship: French
Canadian Permanent Resident

EDUCATION

1993	PhD Thesis in Endocrinology. Université Paris 6, France
1992	Certificate of Statistics applied to Medicine and Biology. Université Paris 6, France
1991	Veterinary Doctoral Thesis
1990	Pre-doctoral degree in Endocrinology. Université Paris 6, France
1988	Graduated from the Ecole Nationale Vétérinaire d'Alfort, France
1982	Baccalauréat C (Maths)

SCIENTIFIC TRAINING

1993-1995	Post-doctoral fellowship in the laboratory of Prof. R. Paul Robertson, The Diabetes Center, University of Minnesota Hospital and Clinics, Minneapolis, MN
1989-1993	PhD. Advisor: Dr. Gérard Reach, INSERM U341, Hôtel-Dieu Hospital, Paris, France

ACADEMIC APPOINTMENTS

2008-	Full Professor, Department of Medicine, University of Montreal, QC.
2007-	Associate Scientific Director – Basic Research, CRCHUM, Montreal, QC
2007-	Associate Director – Research, Montreal Diabetes Research Centre, QC, Canada
2006-	Adjunct appointments, Departments of Nutrition and Biochemistry, University of Montréal, QC, Canada
2005-	Associate Professor, Department of Medicine, University of Montreal, QC
2005-	Scientist, CRCHUM, Montreal, QC
2000-2005	Affiliate Assistant Professor, Department of Medicine, University of Washington, Seattle WA
1998-2005	Principal Scientist, Pacific Northwest Research Institute, Seattle WA
1998-2005	Attending Veterinarian, Pacific Northwest Research Institute, Seattle, WA
1995-	Scientist, INSERM U341, Hôtel-Dieu Hospital, Paris, France
1993-1995	Post-Doctoral Associate, University of Minnesota, Minneapolis, MN

HONORS AND AWARDS

2009	The Canadian Diabetes Association – Great West Life, London Life et Canada Life Young Scientist award
2006-2013	Canada Research Chair (Tier 1) in Diabetes and Pancreatic Beta-Cell Function
2006	Apollinaire Bouchardat Prize, Journées Annuelles de Diabétologie de l'Hôtel-Dieu
2004	Education Outreach Service Award, Northwest Association for Biomedical Research
2003	Thomas R. Lee Career Development Award, American Diabetes Association
2001	Atorvastatin Research Award (declined)
1996	Jean Leray Award, European Society for Biomaterials
1994	Midwest Trainee Investigator Award, American Federation for Clinical Research
1994	Post-doctoral Fellowship, ALFEDIAM
1993	Lavoisier Fellowship, French Ministry of Foreign Affairs
1993	Albert Renold Fellowship, EASD
1992	BIOMAT 92 Prize, Association pour le développement des Biomatériaux
1991	Doctoral fellowship, L'Aide aux Jeunes Diabétiques
1989	Pre-doctoral fellowship, Fondation pour la Recherche Médicale

CURRENT GRANT SUPPORT

2001-2011	National Institutes of Health R01 DK 58096 "Mechanisms of Fatty Acid Inhibition of the Insulin Gene". Total direct costs: US$ 1,000,000. Role: PI.
2008-2011	Canadian Institutes of Health Research "The role of GPR40 and GPR120 in pancreatic beta-cell function." Total direct costs : $366,000. Role: PI.
2004-2009	National Institutes of Health R21/R33 DK 070146 "Proteomics and Metabolomics Studies of Type 1 Diabetes". Total direct costs: US$ 385,041 (subcontract). Role: Co-investigator.
2009-2012	Canadian Cystic Fibrosis Foundation Small Team Grant «Diabetes and inflammation: a better understanding for a better control of CF disease» Total direct costs for our group: $ 180,000. Role: Co-investigator.
2009-2010	Addex Pharmaceuticals «Characterization of GLP-1 positive allosteric modulators». Total direct costs: $ 118,104. Role: PI.

PAST GRANT SUPPORT

2007	Merck Frost Ltd "Preservation of beta-cell function by Sitagliptin in a model of glucolipotoxicity in vivo. Total direct costs: $61,024
2007	Amylin Pharmaceuticals Inc. "Preservation of beta-cell function by Exenatide in a model of glucolipotoxicity in vivo" Total direct costs : $58,072
2005-2007	National Institutes of Health R21 DK 070598 "Role of GPR40 in the regulation of insulin secretion". Total direct costs: US$ 200,000. Role: PI
2005-2008	Canadian Institutes of Health Research Operating Grant #145308 "Mechanisms of fatty-acid inhibition of insulin gene expression in the pancreatic beta-cell". Total direct costs: Can$ 261,689. Role: PI (relinquished upon renewal of NIH R01DK 58096)

2002-2005 American Diabetes Association Career Development Award "Mechanisms of Fatty-Acid Potentiation of Insulin Secretion". Total direct costs: $ 750,000. Role: PI (relinquished upon relocating to Canada).

2001-2003 American Heart Association Grant-in-Aid "The role of intracellular ceramide generation in beta-cell dysfunction of obesity-associated diabetes mellitus". Total direct costs: $ 100,000

2000-2001 American Diabetes Association Research Award "Neutral lipid dysregulation of the pancreatic beta-cell". Total direct costs: $ 200,000 (relinquished upon activation of NIH R01 DK 58096).

PROFESSIONAL SERVICES

2008- Member, Juvenile Diabetes Research Foundation Medical Science Review Committee, Beta Cell Replacement and Regeneration Study Section for Innovative Grants.

2007- Vice-Chair, Personal Award Committee, Canadian Diabetes Association

2006- Member, Personnel Award Committee, Canadian Diabetes Association

2006- Steering Committee, Montreal Diabetes Research Center

2006-2011 Editorial Board of *The Journal of Biological Chemistry*

2006-2010 Member, Cellular Aspects of Diabetes and Obesity Study Section, NIDDK, US National Institutes of Health

2006-2011 Editorial Board of *Diabetes*

2002- Abstract selection committee, American Diabetes Association National Meeting

2001-2007 Research Grant Review Committee, American Diabetes Association.

Chair from 2006-07-01 to 2007-06-30.

2000-2004 Editorial Board of *Endocrinology*

Ad Hoc manuscript reviews:

Cell Metabolism
Diabetologia
Endocrinology
FEBS letters
Hormone and Metabolic Research
Journal of Clinical Investigation
Metabolism
The Journal of Lipid Research
Molecular and Cellular Biology
American Journal of Physiology.
Proc Natl Acad Sci USA
Nature Reviews Drug Discovery

Ad Hoc grant reviews:

Canadian Institutes of Health Research (Metabolism committee)
VA Merit Review Boards
Diabetes UK
French National Research Agency

LANGUAGES

French, mother tongue; English, fluent.

MEMBERSHIPS

2009- Canadian Diabetes Association – Clinical and Scientific Section

2007- Diabète Québec

2003- American Society for Biochemistry and Molecular Biology

1995- American Diabetes Association (ADA)

1991- European Association for the Study of Diabetes (EASD).

1990- Association de Langue Française pour l'Etude du Diabète et des Maladies Métaboliques (ALFEDIAM)

INSTITUTIONAL COMMITTEES AND FUNCTIONS

2007- Associate Scientific Director – Basic Science, CHUM Research Center

2007- Associate Director – Research, Montreal Diabetes Research Centre, QC, Canada

2006- Member, Scientific Committee, CRCHUM 2010

2006- Member, Steering Committee, Montréal Diabetes Research Centre

2005-2007 Member, Institutional Animal Care and Use Committee, CRCHUM

1998-2005 Attending Veterinarian, Pacific Northwest Research Institute, Seattle, WA

1998-2005 Member, Institutional Animal Care and Use Committee, Pacific Northwest Research Institute, Seattle, WA

TRAINEES & TEACHING

Post-doctoral fellows

2009- Mourad Ferdaoussi.

2008- Bader Zarrouki. Supported by the Montreal Diabetes Center / Merck Frosst Post-doctoral fellowship (2008-2011)

2007- Melkam Kebede. Supported by a post-doctoral fellowship from the Canadian Diabetes Association (2009-2011)

2006-2009 Thierry Alquier. Supported by a post-doctoral fellowship from the Canadian Diabetes Association (2006-2009)

2005-2009 Ghislaine Fontés. Supported by a post-doctoral fellowship from the Canadian Diabetes Association (2007-2009)

2003-2008 Derek Hagman. Supported by a Ruth L. Kirschstein National Research Service Award from the US National Institutes of Health (2005-2008)

Graduate students

2008 Meriem Semache – Biochemistry, University of Montréal

2006- Julie Amyot – Biochemistry, University of Montréal. Supported by a doctoral award from the Fonds de la Recherche en Santé du Québec (2009-2011)

1996-2000 Isabelle Briaud – Endocrinology, University Paris 6

Undergraduate students

2009 Valérie Bergeron – Summer Internship, Biochemistry, University of Montréal

2008	Sarah Bouhabel – Summer Internship, Nutrition, University of Montréal
2008	Lucie Corriveau – Summer Internship, Nutrition, University of Montréal
2007	Thi Haiyen Nguyen – Summer Internship, Biochemistry, University of Montréal
2006-2007	Ahn-Tuyet Luong – Summer Internship, Biochemistry, University of Montréal
2002-2003	Marco Ugas - Undergraduate student, Seattle University
2000-2003	Sarah Parker - Undergraduate student, Seattle University
1997-1998	Sophie Jacqueminet - Pre-doctoral research year, University Paris 6

Teaching

2009	NUT 3033 - Supervision of mini-dissertations in nutrition – 2 students
2008	NUT 6627 (3 hours)
2008	NUT 3033 - Supervision of mini-dissertations in nutrition – 2 students
2006	NUT 7050 and 7051 (1 hour) – Department of Medicine, University of Montreal
2001 – 2005	Group leader for small group discussions in the Endocrine Systems Core Course (Human Biology 544) for 2nd-year medical students, University of Washington Department of Medicine.

Thesis committees

2009	Julie Dusseault, Ph.D. candidate, Biomedical Sciences, University of Montreal, Member of the jury.
2009	Marco Gasparrini, MSc candidate, Biomedical Sciences, McGill University, Member of the follow-up committee.
2008	Andrei Oprescu, Ph.D. candidate, Institute of Medical Science, University of Toronto, External member
2008	Dimitri Favre, Ph.D. candidate, University of Geneva, External member
2008	Valérie Baldacchino, Ph.D. candidate, Biomedical Sciences, University of Montreal, President
2008	Chih Chang Wei, Ph.D. candidate, Biomedical Sciences, University of Montreal, Dean representative
2007	Karine Bédard, Ph. D. candidate, Biochemistry Department, University of Montreal.
2007	Karin Fink, Ph. D. candidate, Biochemistry Department, University of Montreal.
2007	Imane Hamana, Ph.D candidate, Nutrition Department, University of Montreal, Pre-doctoral jury.
2007	Katherine Robertson, PhD candidate, Experimental Medicine, McGill University – External member.
2006	Amélie Pelletier, PhD candidate, Biomedical Sciences, University of Montréal
2006	Houssein Hajj Hassan, PhD candidate, Molecular Biology, University of Montréal
2005	Serge Hardy, PhD candidate, Biochemistry, University of Montréal
2000	Isabelle Briaud, PhD candidate, Université Paris 6 (Endocrinologie) – Research Director
1997	Nathalie Dachicourt, PhD candidate, Physiology, Université Paris 7

CONSULTING

2009- Addex Pharmaceuticals

2006- Beta-cell Exenatide Advisory Board, Amylin Lilly Alliance

2005- Merck Frosst Canada

10/2005 Takeda

CIVIC ACTIVITIES

2004 - 2005 French Studies Advisory Board, College of Arts and Sciences, University of Washington, Seattle, WA (Chair from 09/04 to 06/05)

2004 - 2005 Chemistry Department Advisory Board, Seattle University, Seattle, WA

1999 - 2002 Board of Trustees, French-American School of Puget Sound, Mercer Island, WA (President from 7/1/00 to 6/30/02).

SEMINARS, EDUCATION AND OUTREACH

Invited Lectures

External

1. Affections endocriniennes à tropisme cutané chez le chat. Séminaire "Peau et Fourrure du Chat" de la Société Française de Félinotechnie, Maisons-Alfort, May 1992.
2. Mécanismes des effets toxiques du glucose sur l'expression du gène de l'insuline. Séminaires de L'Institut Cochin de Génétique Moléculaire. Paris, June 1996.
3. Peut-on construire une cellule insulino-sécrétrice ? Les possibilités de l'ingénierie cellulaire. Xème réunion scientifique de l'Aide aux Jeunes Diabétiques. Paris, November 1996.
4. Towards the development of a bioartificial pancreas for the treatment of Diabetes Mellitus. 1996 Jean Leray Award Lecture. 13th European Conference on Biomaterials. Göteborg, Sweden, September 1997.
5. Glucotoxicity, lipotoxicity, or both? 60th National Scientific Meeting, American Diabetes Association, San Antonio, TX, June 2000.
6. Stress oxydatif, insulinosécrétion, et insolinorésistance. Journées de Diabétologie de l'Hôtel-Dieu, May 2001.
7. Fatty-acid dysregulation of the pancreatic beta-cell. Inserm U376, Montpellier, France, January 2002.
8. Fatty-acid dysregulation of the pancreatic beta-cell. University of California San Francisco Diabetes Research Center Seminar, April 2002.
9. Lipotoxicity and Type 2 diabetes: Do beta-cells get fat…and does it matter? University of Wisconsin, Seminars of the Department of Biochemistry, April 2003.
10. Lipotoxicity and Pancreatic beta-cells. Korean Diabetes Association. Seoul, Republic of Korea, May 2003.
11. Fatty acids and pancreatic beta-cell function: The good and the bad. Tularik Corp., South San Francisco, CA, July 2003.

12. Impairment of beta-cell function by hyperlipidemia. 18th International Diabetes Federation Congress, Paris, France, August 2003.
13. Impairment of pancreatic beta-cell function by chronic hyperlipidemia. Amgen Corp., Seattle, WA, November 2003.
14. Long-term effects of FFA on insulin secretion. ADA research symposium, Integrative role of fatty acids in metabolic regulation: implications for obesity and diabetes. Newport, RI, April 2004.
15. Glucolipotoxicity of the pancreatic beta-cell. 47th Journées Internationales d'Endocrinologie Clinique. Paris, France, April 2004.
16. Fatty acids and pancreatic beta-cell function. Merck & Co., Inc., Rahway, NJ, July 2004.
17. Effets chroniques des acides gras sur la fonction bêta-pancréatique. Séminaire de Recherche, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Canada, September 2004.
18. Role of lipotoxicity in beta-cell dysfunction. 5th Annual Rachmiel Levine Symposium. Los Angeles, CA, October 2004.
19. Lipotoxicity in the pancreatic beta-cell. Metabolism, Endocrinology, and Diabetes Research Seminars, University of Michigan School of Medicine, Ann Arbor, MI, May 2005.
20. Regulation and dysregulation of the insulin gene by glucose and fatty acids. FASEB summer research conference "Nutrient regulation of gene expression" , Tucson, AZ, July 2005.
21. Fatty acids and pancreatic beta-cell function: two sides of one coin. Islet Biology Center Seminar Series, University of Vermont, Burlington, VT, October 2005.
22. Fatty acids and pancreatic beta-cell function: two sides of one coin. Metabolism Interest Group, University of Utah School of Medicine, Salt Lake City, UT, December 2005.
23. Fatty Acid Inhibition of Insulin Gene Expression. Keystone Symposium "Understanding Islet Biology", Taos, NM, February 2006.
24. Lipid Deposition in Islets as a Cause of Beta-Cell Dysfunction. 66th National Scientific Meeting, American Diabetes Association, Washington, DC, June 2006.
25. Beta cell function and survival – importance of the metabolic milieu. 2nd Canadian Beta Cell Working Group, Toronto, ON, November 2006.
26. Debate on Fatty Acid Effects on Beta-cell Function: Fatty Acids Are Bad for You. Translating Islet Biology into Diabetes Therapy Research Symposium, American Diabetes Association, Stone Mountain, Georgia, March 2007.
27. Fatty Acids and Pancreatic Beta-Cell Function. Cellular Degeneration and Disease Retreat, Merck, Pocono Mountains, Pennsylvania, April 2007.
28. Fatty Acids and Pancreatic Beta-Cell Function. Wyeth Pharmaceuticals, Cambridge, MA, June 2007.
29. Fatty Acids and Pancreatic Beta-Cell Function : Two Sides of the Coin. Pacific Northwest Research Institute, Seattle, WA, December 2007.
30. Fatty Acids and Pancreatic Beta-Cell Function. City-Wide Endocrine Rounds, Banting and Best Diabetes Centre, University of Toronto, January 2008.
31. Glucolipotoxicity of the pancreatic Beta-Cell : myth or reality? Molecular mechanisms of glucolipotoxicity in diabetes, Biochemistry society, University College Dublin, Ireland. March 2008
32. Glucolipotoxicity of the pancreatic Beta-Cell. 42nd Annual Scientific Meeting of the European Society for Clinical Investigation. European Journal of Clinical Investigation Geneva, Switzerland 38/Suppl 1 A406, March 2008

33. Fatty Acids and Pancreatic Beta-Cell Functions: Two Sides of the Coin. McGill University – Montreal Children's Hospital Research Institute, April 2008.
34. Fatty Acids and Pancreatic Beta-Cell Functions: the Two Sides of the Coin. Bristol-Myers Squibb, New Jersey, April 2008
35. Fatty Acids and Pancreatic Beta-Cell Functions: Two Sides of the Coin. University of Pittsburgh, Endocrine Research Conference, Pittsburgh PA, May 2008.
36. Fatty Acids and Pancreatic Beta-Cell Functions: Two Sides of the Coin. Wayne State University – Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI, May 2008.
37. GPR-40 Agonists or Antagonists? G-Protein coupled receptors in the beta-cell some orphans find a home symposium, American Diabetes Association, San Francisco CA, June 2008.
38. Beta Cell Glucolipotoxicity from a Pre-clinical Research Perspective, Canadian Diabetes Association, Montreal, October 2008.
39. GPR40: A drug target for type 2 diabetes?, Addex Pharma, Genève, November 2008
40. Do beta-cells get fat, and does it matter?, Département de biologie cellulaire et de morphologie, Université de Lausanne, November 2008
41. GPR40 : A drug target for type 2 diabetes?, Department of Physiology, University of Toronto, December 2008
42. Pancreatic beta-cell failure in type 2 diabetes: Lessons from pre-clinical studies. Annual meeting of the Society for Comparative Endocrinology, Quebec City, Qc, Canada, June 1, 2009
43. Fatty acids play Dr Jekyll and Mr Hyde in pancreatic beta-cell. IDF Congress, Montreal, Qc, Canada, October 2009
44. Glucolipotoxicité de la cellule beta-pancréatique. CHUS Endocrine Rounds, Sherbrooke, November 11, 2009
45. Fatty acids and pancreatic beta-cell function : Dr Jekyll and Mr Hyde. Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania, Philadelphia, PA, USA, January 2010.

Internal

1. Lipotoxicity of the pancreatic beta-cell. Seminars of the Diabetes and Endocrinology Research Center, University of Washington, WA, December 2000.
2. Fatty Acids and Pancreatic Beta-Cell Function. Diabetes Gene Discovery Group Annual Retreat, Montréal, QC, October 2005.
3. Acides gras et fonction de la cellule bêta-pancréatique. CHUM Annual Retreat, Montréal, QC, November 2005.
4. Acides gras et fonction de la cellule bêta-pancréatique. Research Seminars of the Department of Biochemistry, University of Montréal, Montréal, QC, December 2005.
5. Acides gras et fonction de la cellule bêta-pancréatique. Research Seminars of the Department of Nutrition (Units 7050 & 7051), University of Montréal, Montréal, QC, January 2006.
6. Acides gras et fonction bêta-pancréatique. Scientific Seminars of the Division of Endocrinology, Department of Medicine, University of Montréal, Montréal, QC, January 2006.
7. Acides gras et fonction de la cellule bêta-pancréatique. Angus Internal Seminars at The Research Center of the University of Montreal Hospital (CR-CHUM). December 2006.
8. Fatty Acids and Pancreatic Beta-Cell Function. First Annual Retreat of the Montreal Diabetes Research Center, January 2007.

9. Rôle de la cellule beta-pancréatique dans la physiopathologie du diabète de type 2. Réunions scientifiques hebdomadaires at the Medicine Department of the Hospital Center of the University of Montreal. May 2007.
10. Acides gras et fonction bêta-pancréatique. Department of Pathology and Cell Biology, Université de Montréal, September 2008.

Meetings

10/2009 Session Co-chair, symposium "Genetic regulation of islet beta-cell function and survival", International Diabetes Association Meeting, Montreal.

10/2009 Session Chair, poster discussion "Insulin insensitivity and the metabolic syndrome", International Diabetes Association Meeting, Montreal.

10/2009 Session Chair, conference "Beta-cell mass in the pathogenesis of type 2 diabetes – is it the critical component?", International Diabetes Association Meeting, Montreal.

11/2008 Organizer, 4th Annual Meeting of the Canadian Beta-cell Working Group, Montréal, QC (supported by an unrestricted educational grant from Merck Frosst Canada).

06/2008 Session Chair, 68th Scientific Sessions of the American Diabetes Association, San Francisco CA.

03/2008 Session Chair, 42nd Annual Scientific Meeting of the European Society for Clinical Investigation, Geneva, Switzerland.

04/2007 Member of the organizing committee of the American Diabetes Association Research Symposium "Translating Islet Biology into Diabetes Therapy"

11/2006 Member of the organizing committee of the American Diabetes Association's meeting "Understanding beta-cell function"

04/2006 Co-organizer (with Dr. Marc Prentki), 2006 Spring Meeting of the Boston-Ithaca Islet Club, Montréal, QC

10/2004 Chair, Session "Type 2 diabetes", WRISG meeting, Catalina Island, CA

04/2004 Co-Chair, Session "Biology of Pancreas Beta and Alpha Cells", Journées Internationales d'Endocrinologie Clinique, Paris, France

03/2004 Panel Member, 2004 Fred Hutchinson Cancer Research Center Career Day, Seattle, WA

08/2003 Co-Chair, Session "Beta-cell adaptation to demand and exhaustion", IDF meeting, Paris, France

05/2003 Co-chair, University of Washington Division of Endocrinology and Metabolism fellow's retreat, Seattle, WA

Outreach

11/2006 "Gluco-lipotoxicity and beta-cell dysfunction in Type 2 diabetes" Best of American Diabetes Association, Pune, Ahmedabad, and Kolkata, India

11/2006 "Fat around the Body : Is It All the Same? " Best of American Diabetes Association, Pune, Ahmedabad, and Kolkata, India

02/2006 "Fat around the Body: Is It All the Same?" 53rd Annual Advanced Postgraduate Course of the American Diabetes Association, San Francisco, CA

05/2005 "The latest in Diabetes Research", Annual Conference of the Washington Association of Diabetes Educators, Tacoma, WA

01/2005 "Do beta-cells get fat…and does it matter?" Endocrine Day Educational Institute. Seattle, WA

11/2004 Panel Member, 2004 Health Care Series – Diabetes: Perspective on Solutions. Seattle City Club, Seattle, WA

03/2004 Mentor, Diabetes Expo, Seattle, WA

03/2004 Speaker, Leadership breakfast for ADA's America's Walk for Diabetes, Seattle, WA

10/2003 Panel member: How do the Veterinarian, Animal Care Staff, and the Investigator work together to address animal research issues and accomplish research goals? 54th American Association for Laboratory Animal Science National Meeting, Seattle, WA

08/2003 Speaker, nurturing dinner for ADA executives and contributors, Seattle, WA

06/2003 Speaker, nurturing dinner for ADA executives and contributors, New Orleans, LA

2002-2005 Member, Northwest Association for Biomedical Research Speaker's Bureau

2002-2004 Organizer, Washington Association for Biomedical Research's annual "Scientist for a day" event, Seattle, WA

PUBLICATIONS

Original, Peer-Reviewed Publications

1. V. Poitout, D. Moatti, G. Velho, G. Reach, R. Sternberg, D.R. Thévenot, D. Bindra, Y. Zhang, G.S. Wilson. In vitro and in vivo evaluation in dogs of a miniaturized glucose sensor. *Trans Am Soc Artif Intern Organs* 1991, 37/3: M298-M300.
2. V. Poitout, D. Moatti-Sirat, G. Reach. Calibration in dogs of a subcutaneous miniaturized glucose sensor using a glucose meter for blood glucose determination. *Biosens Bioelectron* 1992, 7: 587-592.
3. D. Moatti-Sirat, F. Capron, V. Poitout, G. Reach, D.S. Bindra, Y. Zhang, G.S. Wilson, D.R. Thévenot. Towards continuous glucose monitoring: in vivo evaluation of a miniaturized glucose sensor implanted for several days in rat subcutaneous tissue. *Diabetologia* 1992, 35: 224-230.
4. V. Poitout, D. Moatti-Sirat, G. Reach, Y. Zhang, G.S. Wilson, F. Lemonnier, J.C. Klein. A glucose monitoring system for on line estimation in man of blood glucose concentration using a miniaturized glucose sensor implanted in the subcutaneous tissue, and a wearable control unit. *Diabetologia* 1993, 36/7: 658-663.
5. D. Moatti-Sirat, V. Poitout, V. Thomé, M.N. Gangnerau, G. Reach, Y. Zhang, F. Lemonnier, J.C. Klein. Elimination of acetaminophen interference in glucose sensors by a composite Nafion membrane: demonstration in rats and man. *Diabetologia* 1994, 37: 610-616.
6. Y. Zhang, Y. Hu, G.S. Wilson, D. Moatti-Sirat, V. Poitout, G. Reach. Elimination of acetaminophen interference in an implantable glucose sensor. *Anal Chem* 1994, 66/7:1183-1188.
7. C. Arbet-Engels, S. Darquy, F. Capron, M.E. Pueyo, S. Di Maria, V. Poitout, G. Reach. A one step method for isolating islets of Langerhans from the porcine pancreas. *Artifi Organs* 1994, 18/8: 570-575.
8. M. Pueyo, S. Darquy, C. Arbet-Engels, V. Poitout, S. Di Maria, F. Capron, G. Reach. A method to obtain monodispersed cells from isolated porcine islets of Langerhans. *Int J Artif Org*, 1995, 18/1: 51-55.
9. V. Poitout, L.E. Stout, M.B. Armstrong, T.F. Walseth, R.L. Sorenson, R.P. Robertson. Morphological and functional characterization of ßTC-6 cells, an insulin-secreting cell line derived from transgenic mice. *Diabetes* 1995, 44: 306-313.

10. D.M. Kendall, V. Poitout, L.K. Olson, R.L. Sorenson, R.P. Robertson. Somatostatin coordinately regulates glucagon gene expression and exocytosis in HIT-T15 cells. *J Clin Invest* 1995, 96:2496-2502.

11. V. Poitout, L. Karl Olson, R.P. Robertson. Chronic exposure of ßTC-6 cells to supraphysiologic concentrations of glucose decreases binding of the RIPE3b1 insulin gene transcription activator. *J Clin Invest* 1996, 97: 1041-1046.

12. V. Gupta, D.G. Wahoff, D.P. Rooney, V. Poitout, D.E.R. Sutherland, D.M. Kendall, R. P. Robertson. The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. *Diabetes* 1997, 46: 28-32.

13. A. Moran, H.J. Zhang, L.K. Olson, J.S. Harmon, V. Poitout, R.P. Robertson. Differentiation of glucose toxicity from ß-cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. *J Clin Invest* 1997, 99:534-539.

14. L.K. Olson, J. Qian, V. Poitout. Glucose rapidly and reversibly decreases insulin gene transcription in INS-1 cells via decrements in STF-1 and C1 activator transcription factor activity. *Mol Endocrinol* 1998, 12: 207-219.

15. V. Poitout, C. Rouault, M. Guerre-Millo, I. Briaud, G. Reach. Inhibition of insulin secretion by leptin in normal rodent islets of Langerhans. *Endocrinology* 1998, 139: 822-826.

16. I. Briaud, C. Rouault, G. Reach, V. Poitout. Long-term exposure of isolated rat islets of Langerhans to supraphysiologic glucose concentrations decreases insulin mRNA levels. *Metabolism* 1999, 48: 319-323.

17. C. Benes, V. Poitout, J.C. Marie, J. Martin-Perez, M.P. Roisin, R. Fagard. Mode of regulation of the extracellular signal-regulated kinases in the pancreatic ß-cell MIN6 and their implication in the insulin gene transcription control. *Biochem J* 1999, 340: 219-225.

18. P.O.T. Tran, C.E. Gleason, V. Poitout, R. P. Robertson. Prostaglandin E2 mediates inhibition of insulin secretion by interleukin-1ß. *J Biol Chem* 1999, 274: 31245-31248.

19. S. Jacqueminet, I. Briaud, C. Rouault, G. Reach, V. Poitout. Inhibition of insulin gene expression by long-term exposure of pancreatic beta-cells to palmitate is dependent upon the presence of a stimulatory glucose concentration. *Metabolism* 2000, 49: 532-536.

20. I. Briaud, C. Rouault, D. Bailbé, B. Portha, G. Reach, V. Poitout. Glucose-induced insulin mRNA accumulation is impaired in islets from neonatal streptozotocin-treated rats. *Horm Metab Res* 2000, 32: 53-56.

21. I. Briaud, J.S. Harmon, C.L. Kelpe, V.B. Segu, V. Poitout. Lipotoxicity of the pancreatic ß-cell is associated with glucose-dependent esterification of fatty acids into neutral lipids. *Diabetes* 2001, 50: 315-321.

22. J.S. Harmon, C.E. Gleason, Y. Tanaka, V. Poitout, R.P. Robertson. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene expression in Zucker Diabetic Fatty rats. *Diabetes* 2001, 50: 2481-2486.

23. M. Guerre-Millo, C. Rouault, P. Poulain, J. André, V. Poitout, J.M. Peters, F.J. Gonzales, J.C. Fruchart, G. Reach, B. Staels. PPARa null mice are protected from high-fat diet-induced insulin resistance. *Diabetes* 2001, 50: 2809-2814.

24. I. Briaud, C.L. Kelpe, L.M. Johnson, P.O.T. Tran, V. Poitout. Differential effects of hyperlipidemia on insulin secretion in islets of Langerhans from hyperglycemic vs. normoglycemic rats. *Diabetes* 2002, 51: 662-668.

25. C.L. Kelpe, L.M. Johnson, V. Poitout. Increasing triglyceride synthesis inhibits glucose-induced insulin secretion in isolated rat islets of Langerhans. A Study Using Adenoviral Expression of Diacylglycerol Acyltransferase. *Endocrinology* 2002, 143: 3326-3332.

26. S. Matsumoto, S. Qualley , S. Goel , D. Hagman, Ian R. Sweet, V. Poitout , D. M. Strong , R. P. Robertson, J. Reems. Effect of the two-layer [University of Wisconsin solution-Perfluorochemical + O_2] method of pancreas preservation on human islet isolation, as assessed by the Edmonton isolation protocol. *Transplantation* 2002, 74: 1414-1419.

27. P.C. Guest, S.M. Abdel-Halim, D.J. Gross, A. Clark, V. Poitout, R. Amaria, C.G. Ostenson, J.C. Hutton. Proinsulin processing in the Goto-Kakizaki (GK) rat. *J Endocrinol* 2002, 175: 637-647.

28. K. Yaekura, R. Julyan, L. Hays, M. Donelan, D. Baskin, V. Poitout, C.J. Rhodes. Insulin secretory deficiency and glucose intolerance in Rab3A *null* mice. *J Biol Chem* 2003, 278: 9715-9721.

29. C.L. Kelpe, P.C. Moore, S.D. Parazzoli, B. Wicksteed, C.J. Rhodes, V. Poitout. Palmitate inhibition of insulin gene expression is mediated at the transcriptional level via ceramide synthesis. *J Biol Chem* 2003, 278: 30015-30021.

30. S. Parker, P.C. Moore, L.M. Johnson, V. Poitout. Palmitate potentiation of glucose-induced insulin release: a study using 2-bromopalmitate. *Metabolism* 2003, 52:1367-1371.

31. R. Roduit, C. Nolan, C. Alarcon, P. Moore, A. Barbeau, V. Delghingaro-Augusto, E. Przybykowski, J. Morin, F. Massé, B. Massie, N. Ruderman, C. Rhodes, V. Poitout, M. Prentki. A Role for the malonyl-CoA / long-chain acyl-CoA pathway of lipid signaling in the regulation of insulin secretion in response to both fuel and non-fuel stimuli. *Diabetes* 2004, 53: 1007-1019.

32. P.C. Moore, M.A. Ugas, D.K. Hagman, S.D. Parazzoli, V. Poitout. Evidence against the involvement of oxidative stress in fatty-acid inhibition of insulin secretion. *Diabetes* 2004, 53: 2610-2616.

33. M. F. Pino, D. Z. Ye, K. D. Linning, C.D. Green, B. Wicksteed, V. Poitout, L. K. Olson. Elevated glucose attenuates human insulin gene promoter activity in INS-1 pancreatic ß cells via reduced nuclear factor binding to the A5/core and Z element. *Mol Endocrinol* 2005, 19: 1343-1360.

34. L. Zhao, M. Guo, T. Matsuoka, D.K. Hagman, S.D. Parazzoli, V. Poitout, R. Stein. The islet beta-cell-enriched MafA activator is a central regulator of insulin gene transcription. *J Biol Chem* 2005, 280: 11887-11894.

35. H. Bihan, C. Rouault, V. Poitout, G. Reach, B. Staels, M. Guerre-Millo. PPARα contributes to the adaptive response of pancreatic islets to hyperglycemia. *FEBS Letters* 2005, 579: 2284-2288.

36. D.K. Hagman, S.D. Parazzoli, V. Poitout. Palmitate inhibits insulin gene expression by altering PDX-1 nuclear localization and reducing MafA expression in isolated rat islets of Langerhans. *J Biol Chem* 2005, 280: 32413-32418.

37. T.O. Metz, J.M. Jacobs, M.A. Gritsenko, G. Fontès, W-J. Qian, D.G. Camp, V. Poitout, R.D. Smith. Characterization of the Human Pancreatic Islet Proteome by Two-Dimensional LC/MS/MS. *J Proteome Research* 2006, 5: 3345-3354.

38. M.G. Latour, T. Alquier, E. Oseid, C. Tremblay, T.L. Jetton, J. Luo, D.C.-H. Lin, V. Poitout. GPR40 is Necessary but not Sufficient for Fatty-Acid Stimulation of Insulin Secretion *in Vivo. Diabetes* 2007, 56:1087-1094.

39. D.K. Hagman, M.G. Latour, S.K. Chakrabarti, G. Fontes, J. Amyot, C. Tremblay, M. Semache, J.A. Lausier, V. Roskens, R.G. Mirmira, T.L. Jetton, V. Poitout. Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets. *Diabetes* 2008, 57:424-431.

40. M. Kebede, T. Alquier, M.G. Latour, M. Semache C. Tremblay, V. Poitout. The Fatty-Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo After High-Fat Feeding. *Diabetes* 2008, 57: 2432-2437.

41. S. Guo, R. Burnette, L. Zhao, N.L. Vanderford, V. Poitout, D.K. Hagman, E. Henderson, S. Ozcan, B. Wadzinski, R. Stein. The stability and transactivation potential of the mammalian MAFA

transcription factor is regulated by Serine 65 Phosphorylation, *J. Biol Chem* 2009, 284: 2759-2765.

42. G. Fontés, M. Semache, D. Hagman, C. Tremblay, R. Shah, C.J. Rhodes, J. Rutter, V. Poitout. Involvement of PAS Kinase and ERK ½ in palmitate inhibition of insulin gene expression in pancreatic beta cells, *Diabetes* 58: 2048-2058, 2009.

43. M-L. Peyot, C. Guay, M.G. Latour, J. Lamontagne, R. Lussier, M. Pineda, N.B. Ruderman, G. Haemmerle, R. Zechner, E. Joly, S.R.M. Madiraju, V. Poitout, M. Prentki. Adipose Triglyceride Lipase is implicated in fuel and non-fuel stimulated insulin secretion. *J. Biol Chem* 2009; 284(25):16848-859.

44. J. Lamontagne, E. Pepin, M-L. Peyot, E. Joly, N.B. Ruderman, V. Poitout, S.R.M. Madiraju, C.J. Nolan, M. Prentki. Pioglitazone acutely reduces insulin secretion and causes metabolic deceleration of the pancreatic β-cell at submaximal glucose concentrations. *Endocrinology* 2009; 150(8): 3465-74

45. T. Alquier, M-L. Peyot, M. G. Latour, M. Kebede, C.M. Sorensen, S. Gesta, C.R. Kahn, R.D. Smith, T.L. Jetton, T.O. Metz, M. Prentki, V. Poitout. Deletion of GPR40 Impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. *Diabetes*, 2009 Nov; 58(11): 2607-15.

46. J. Chen, F. Fontes, G. Saxena, V. Poitout, A. Shalev. Lack of TXNIP protects against mitochondria-mediated apoptosis, but not against fatty acid-induced, ER-stress-mediated beta cell death. Diabetes 2010; 59: 440-447.

47. G. Fontes, G. K. Hagman, M. G. Latour, M. Semache, V. Poitout. Lack of preservation of insulin gene expression by a glucagon-like peptide 1 agonist or a dipeptidyl peptidase 4 inhibitor in an in vivo model of glucolipotoxicity. Diabetes Research and Clinical Practice 2010 Mar; 87(3):322-8.

48. G. Fontés, D. K. Hagman, B. Zarrouki, M. G. Latour, M. Semache, V. Roskens, P. C. Moore, S. Ghosh, G. d'Assignies, A. Tang, S. M. Najjar, M. Prentki, C. J. Rhodes, T. L. Jetton, V. Poitout. Glucolipotoxicity In Vivo Age-Dependently Impairs Beta-Cell Function in Rats . Submitted for publication.

Invited Reviews and Book Chapters

1. P. Bourdeau, V. Poitout. Dysendocrinies féline à expression cutanée. Première partie: La thyroïde et les surrénales. Le Point Vétérinaire. 1992, 24/148: 55-64.

2. V. Poitout, P. Bourdeau. Dysendocrinies féline à expression cutanée. Deuxième partie: Le pancréas endocrine et les gonades. Le Point Vétérinaire. 1992, 24/149: 623-633.

3. G.S. Wilson, Y. Zhang, G. Reach, D. Moatti-Sirat, V. Poitout, D.R. Thévenot, F. Lemonnier, J.C. Klein. Progress towards the development of an implantable sensor for glucose. *Clin Chem* 1992, 38/9: 1613-1617.

4. G. Reach, D. Moatti-Sirat, V. Poitout. Continuous glucose sensing for the treatment of diabetes mellitus. *Analysis* 1993, 21/2: M35-M39.

5. V. Poitout, D. Moatti-Sirat, G. Reach. Development of a glucose sensor for glucose monitoring in man: the disposable implant concept. *Clin Mater* 1994, 15: 241-246.

6. G. Reach, V. Thomé, V. Poitout, G.S. Wilson, J.C. Klein. Le futur de l'autosurveillance glycémique: entre le rêve et la réalité. In Journées de Diabétologie de l'Hôtel-Dieu 1995, Flammarion, Paris, pp 191-205.

7. G. Reach, V. Poitout, S. Darquy. L'avenir de la greffe d'îlots de Langerhans. In C. Chatelain et C. Jacobs ed. Séminaires d'Uro-Néphrologie. XXIIème série 1996, Masson, Paris, pp. 126-136.

8. V. Poitout, R. P. Robertson. An integrated view of ß-cell dysfunction in Type II diabetes. In *Annu Rev Med* Vol. 47, Coggins C.H., Hancock E.W., Levitt L.J. eds. Annual Reviews Inc., Palo Alto, 1996, pp. 69-83.

9. V. Poitout, L.K. Olson and R.P. Robertson. Insulin secreting cell lines: classification, characteristics and potential applications. *Diabete Metab* 1996, 22: 7-14.

10. R. P. Robertson, E.R. Seaquist, T.F. Walseth, H.J. Zhang, J.B. Redmon, V. Poitout, D.M. Kendall. GTP binding proteins and regulation of pancreatic islet function: heterotrimeric proteins, insulin and glucagon genes, and hormone secretion. In Diabetes Mellitus. A fundamental and clinical text. 1st edition, Le Roith D., Olefsky J.M., Taylor S. eds. Lippincott - Raven, 1996 pp. 49-56.

11. V. Poitout, M. Guerre-Millo. La leptine a-t-elle un effet direct sur les cellules ß-pancréatiques ? *Med Sci* 1998, 14: 227.

12. V. Poitout, C. Rouault, M. Guerre-Millo, G. Reach. Does leptin regulate insulin secretion? *Diabete Metab* 1998, 24: 321-326.

13. G. Reach, S. Darquy, V. Poitout. L'utilisation de cellules des îlots de Langerhans en thérapie cellulaire. *Transfus Clin Biol* 1998, 5: 88-96.

14. R.P. Robertson, J. Harmon, Y. Tanaka, G. Sacchi, P.O.T. Tran, C. Gleason, V. Poitout. Glucose toxicity of the beta-cell: cellular and molecular mechanisms. In Diabetes Mellitus. A fundamental and clinical text. 2nd edition, Le Roith D., Olefsky J.M., Taylor S. eds. Lippincott - Raven, 2000, pp. 125-132.

15. V. Poitout, M. Guerre-Millo. Récepteurs de la leptine de la cellule ß. Médecine-Thérapeutique-Endocrinologie Vol 2, hors série n° 2, 2000, pp. 55-60.

16. R.P. Robertson, J. Harmon, Y. Tanaka, G. Sacchi, P.O.T. Tran, C. Gleason, V. Poitout. Glucose toxicity of the pancreatic beta-cell. In Molecular basis of Pancreas Development and Function. Habener J.F. and Hussain M. eds. Kluwer Academic Publishers, 2001, pp. 47-66.

17. V. Poitout, Y. Tanaka, G. Reach, R.P. Robertson. Stress oxydatif, insulinosécrétion, et insulinorésistance. In Journées de Diabétologie Hôtel-Dieu, Médecine-Sciences Flammarion, 2001 pp. 75-86.

18. V. Poitout, R.P. Robertson. Secondary β-cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity. *Endocrinology* 2002 143:339-342.

19. V. Poitout. Lipid partitioning in the pancreatic β-cell: physiologic and pathophysiologic implications. *Curr Opin Endocrinol Diabetes* 2002, 9: 152-159.

20. V. Poitout. The ins and outs of fatty acids on the pancreatic beta-cell. *Trends Endocrinol Metab* 2003, 14:201-203.

21. R.P. Robertson, J. Harmon, P.O. Tran, V. Poitout: beta-Cell Glucose Toxicity, Lipotoxicity, and Chronic Oxidative Stress in Type 2 Diabetes. *Diabetes* 2004, 53 Suppl 1:S119-124.

22. V. Poitout, I. Briaud, C.L. Kelpe, D.K. Hagman. Glucolipotoxicity of the pancreatic beta-cell. Annales d'Endocrinologie 2004, 65:37-41.

23. V. Poitout, R. Stein, C.J. Rhodes. Insulin gene expression and biosynthesis. In: International Textbook of Diabetes Mellitus, Third Edition. DeFronzo R.A., Ferraninni E., Keen H., and Zimmet P. eds. John Wiley and sons, 2004, pp.97-123.

24. V. Poitout. News and Views Editorial: Beta-cell lipotoxicity: burning fat into heat? *Endocrinology* 2004, 145:3563-3565.

25. V. Poitout, D. Hagman, R. Stein, I. Artner. R.P. Robertson, J.S. Harmon. Regulation of the insulin gene by glucose and fatty acids. *J Nutr* 2006, 136:873-876.

26. V. Poitout. Prix Apollinaire Bouchardat 2006 : Acides gras et fonction de la cellule bêta-pancréatique. In Journées de Diabétologie Hôtel-Dieu, Médecine-Sciences Flammarion, 2006, pp 37-46.
27. S.R.M. Madiraju, V. Poitout. News and Views Editorial : GCPRs and Insulin Secretion : 119 and Counting. *Endocrinology* 2007, 148: 2598-2600.
28. V. Poitout, R.P. Robertson : Glucolipotoxicity : Fuel Excess and Beta-cell Dysfunction. *Endocrine Reviews* 2008;29(3):351-66.
29. V. Poitout, Phospholipid hydrolysis and insulin secretion: a step towards solving the Rubik's cube. *Am J Physiol Endocrinol Metab* 2008 Feb;294(2):E214-6
30. V. Poitout. Glucolipotoxicity of the pancreatic beta-cell: Myth or reality? *Biochem. Soc. Trans.* 2008, 36, 901-904.
31. M.A. Kebede, T. Alquier, M.G. Latour, V. Poitout. Lipid receptors and islet function: therapeutic implications? *Diabetes, Obesity & Metabolism* 2009, Nov; 11 Suppl 4:10-20.
32. T. Alquier, V. Poitout. GPR40: Good Cop, Bad Cop? *Diabetes* 2009, Vol. 58, 1035-1036.
33. V. Poitout, J. Amyot, M. Semache, B. Zarrouki, D.K. Hagman, G. Fontés. Glucolipotoxicity of the pancreatic beta-cell. BBA – Molecular and Cell Biology of Lipids 2010 March 1801(3): 289-298.
34. T. Ntimbane, B. Comte, G. Mailhot, Y. Berthiaume, V. Poitout, M. Prentki, R. Rabasa-Lhoret, E. Levy. Cystic Fibrosis-Related Diabetes : From CFTR Dysfunction to Oxidative Stress. *Clin Biochem* Rev. 2009 Nove;30(4): 153-77.

Abstracts

1. V. Poitout, D. Moatti, G. Velho, G. Reach, R. Sternberg, D.R. Thévenot, D. Bindra, Y. Zhang, G.S. Wilson. In vivo evaluation of a glucose sensor implanted in the subcutaneous tissue of conscious dogs. Artificial Insulin Delivery Systems-Pancreas and Islets Transplantation. Amsterdam, January 1991.
2. D. Moatti, V. Poitout, G. Reach, R.Sternberg, D.R. Thévenot, D. Bindra, Y. Zhang, G.S. Wilson. A simple method for assessing the stability of subcutaneous glucose sensors. Artificial Insulin Delivery Systems Pancreas and Islets Transplantation. Amsterdam, January 1991.
3. D. Moatti, V. Poitout, G. Velho, R. Sternberg, D.R. Thévenot, D. Bindra, G.S. Wilson, G. Reach. A method for evaluating in vivo in rats the characteristics of a glucose sensor, including its lifespan. First European Conference on Biomedical Engineering. Nice, February 1991.
4. D. Moatti, V. Poitout, G. Reach, D. Bindra, Y. Zhang, G.S. Wilson, D.R. Thévenot. Mesure de la glycémie au moyen d'un capteur de glucose miniature implanté pendant plusieurs jours dans le tissu sous cutané du rat. *Diabete Metab* 1991; 17: III.
5. V. Poitout, D. Moatti, G. Velho, G. Reach, R. Sternberg, D.R. Thévenot, D. Bindra, Y. Zhang, G.S. Wilson. In vitro and In vivo evaluation in dogs of a miniaturized glucose sensor. *Am Soc Artific Intern Organs*. Chicago, April 1991.
6. G. Reach, D. Moatti, V. Poitout, G. Velho, R. Sternberg, D.R. Thévenot, D. Bindra, G.S. Wilson. Long term evaluation of a miniaturized glucose sensor implanted in the subcutaneous tissue of rats: evidence for a rapid subcutaneous glucose kinetics. International Diabetes Federation. Washington, June 1991.
7. D. Moatti-Sirat, V. Poitout, G. Reach, G.S. Wilson, D.R. Thévenot. Use of the Error Grid Analysis to assess the accuracy of glucose determination with a subcutaneous glucose sensor. Artificial Insulin Delivery Systems - Pancreas and Islet Transplantation. Igls, Autriche, January 1992.
8. G. Reach, D. Moatti-Sirat, V. Poitout, D.R. Thévenot, G.S. Wilson. Biocapteur pour la surveillance continue de la glycémie dans le diabète insulinodépendant. Journées du Groupe Français de

Bioélectrochimie et le GAMS (Commission Electrochimie) Ecole Supérieure de Physique Chimie. Paris, June 1992.

9. V. Poitout, D. Moatti-Sirat, G. Reach. Développement d'un capteur de glucose: le concept d'implant jetable. BIOMAT. Bordeaux, October 1992.

10. S. Darquy, F. Capron, M.E. Pueyo, V. Poitout, C. Arbet-Engels, G. Reach, J. Honiger, E. Muscat, C. Collier. Nouveau procédé de microencapsulation d'îlots de Langerhans utilisant un hydrogel d'un matériau biocompatible, l'AN 69: Résultats préliminaires. BIOMAT. Bordeaux, October 1992.

11. C. Arbet-Engels, S. Darquy, S. Di Maria, V. Poitout, F. Capron, M.E. Pueyo, G. Reach. Isolement de masse d'îlots de Langerhans à partir du pancreas de porc par une méthode en une étape ne faisant pas intervenir l'opérateur. BIOMAT. Bordeaux, France. October 1992.

12. G. Reach, V. Poitout, D. Moatti-Sirat. Development of a continuous glucose monitoring system. 14ème conférence internationale IEEE-EMBS. Paris, October 1992.

13. V. Poitout, D. Moatti-Sirat, G. Reach. Calibration d'un capteur de glucose sous cutané chez le chien dans des conditions proches de celles d'un patient diabétique. *Diabete Metab* 1992; 18:XVIII.

14. V. Poitout, D. Moatti-Sirat, G. Reach. In vivo calibration of a subcutaneous miniaturized glucose sensor under clinical conditions in dog. *Diabetologia* 35/Suppl.1: A205.

15. V. Poitout, D. Moatti-Sirat, G.Reach, Y. Zhang, G.S. Wilson, F. Lemonnier, J.C. Klein. Glucose sensing in human subcutaneous tissue: preliminary results. *Int J Artif Org* 1992; 15/9: 523.

16. V. Poitout, D. Moatti-Sirat, G.Reach, Y. Zhang, G.S. Wilson, F. Lemonnier, J.C. Klein. On line estimation of blood glucose concentration with a subcutaneous glucose sensor in man. *Horm Metab Res* 1993; 25/1: 64.

17. S. Darquy, J. Honiger, M.E. Pueyo, F. Capron, V. Poitout, C. Arbet-Engels, G. Reach, C. Collier, E. Muscat. The use of a hydrogel of AN 69, a biocompatible biopolymer of acrylonitrile, for the design of a bioartificial pancreas: preliminary studies. *Horm Metab Res* 1993; 25/1: 54.

18. M.E. Pueyo, S. Darquy, C. Arbet-Engels, V. Poitout, S. Di Maria, F. Capron, G. Reach. Preparation of functionnal dispersed cells from isolated porcine islets of Langerhans. *Horm Metab Res* 1993; 25/1: 65.

19. S. Di Maria, S. Darquy, C. Arbet-Engels, V. Poitout, M.E. Pueyo, G. Reach. Insulin secretion in response to glucose by cryopreserved porcine islets of Langerhans: effect of the glucose concentration of culture medium after thawing. *Horm Metab Res* 1993; 25/1: 62.

20. C. Arbet-Engels, S. Darquy, S. Di Maria, V. Poitout, F. Capron, M.E. Pueyo, G. Reach. A one step method for isolating islets of Langerhans from the porcine pancreas without operator intervention. *Horm Metab Res* 1993; 25/1: 50.

21. V. Poitout, D. Moatti-Sirat, G. Reach, Y. Zhang, G.S. Wilson, F. Lemonnier, J.C. Klein. Mesure en continu de la glycémie chez l'homme avec un capteur de glucose sous cutané. *Diabete Metab* 1993, 19: IV.

22. S. Darquy, J. Honiger, M.E. Pueyo, F. Capron, V. Poitout, C. Arbet-Engels, G. Reach, C. Collier, E. Muscat. Utilisation d'un hydrogel d'AN 69, un copolymère d'acrylonitrile, pour la réalisation d'un pancreas bioartificiel: études préliminaires. *Diabete Metab* 1993, 19: XXV.

23. C. Arbet-Engels, S. Darquy, S. Di Maria, V. Poitout, F. Capron, M.E. Pueyo, G. Reach. A one step, non operator directed method for isolating islets of Langerhans from the porcine pancreas. International Congress on Pancreas and Islets Transplantation. Amsterdam, June 1993.

24. S. Darquy, J. Honiger, M.E. Pueyo, F. Capron, V. Poitout, C. Arbet-Engels, G. Reach, C. Collier, E. Muscat. Microencapsulation of islets of Langerhans with a hydrogel of AN 69, a copolymer of

acrylonitrile, for the design of a bioartificial pancreas. International Congress on Pancreas and Islets Transplantation. Amsterdam, June 1993.

25. M.E. Pueyo, S. Darquy, C. Arbet-Engels, V. Poitout, S. Di Maria, F. Capron, G. Reach. A method to obtain monodispersed cells from isolated porcine islets of Langerhans. International Congress on Pancreas and Islets Transplantation. Amsterdam, June 1993.

26. V. Poitout, D. Moatti-Sirat, G.Reach, Y. Zhang, G.S. Wilson, F. Lemonnier, J.C. Klein. Evaluation in human volunteers of a glucose monitoring system using an on line calibration procedure. *Diabetes* 1993, 42/Suppl.1: 176A.

27. S. Darquy, J. Honiger, M.E. Pueyo, F. Capron, V. Poitout, G. Reach, C. Collier, E. Muscat. Use of a biocompatible biomaterial (AN 69) for microencapsulation of islets of Langerhans. *Diabetes* 1993, 42/Suppl.1: 139A.

28. V. Poitout, D. Moatti-Sirat, G. Reach, Y. Zhang, G.S. Wilson, F. Lemonnier, J.C. Klein. Evaluation in man of a continuous glucose monitoring system. *Int J Artif Org* 1993, 16/6: 433.

29. D. Moatti-Sirat, V. Poitout, V. Thomé, M.N. Gangnerau, G.Reach, Y. Zhang, G.S. Wilson, F. Lemonnier, J.C. Klein. Elimination of acetaminophen interference in glucose sensors by a nafion membrane: demonstration in rats and man. *Int J Artif Org* 1993, 16/6: 433.

30. S. Darquy, J. Honiger, F. Capron, V. Poitout, G. Reach, C. Collier, E. Muscat. Microencapsulation of islets of Langerhans with a hydrogel of AN 69 for the design of a bioartificial pancreas. *Int J Artif Org* 1993, 16/6: 411.

31. V. Poitout, D. Moatti-Sirat, V. Thomé, M.N. Gangnerau, Y. Zhang, G.S. Wilson, F. Lemonnier, J.C. Klein, G. Reach. Evaluation in rats and man of a glucose sensor insensitive to acetaminophen. *Diabetologia* 1993, 36/Suppl.1: A152.

32. S. Darquy, J. Honiger, F. Capron, V. Poitout, C. Collier, E. Muscat, G. Reach. Micro and macro encapsulation of islets of Langerhans in a biocompatible material for the design of a bioartificial pancreas. *Diabetologia* 1993, 36/Suppl.1: A14.

33. G. Reach, D. Moatti-Sirat, V. Poitout, V. Thomé. Experience with a miniaturized glucose sensor in man. BME COMAC. Ury, June 1993.

34. S. Darquy, P. Petruzzo, G. Ruiu, F. Polo, V. Poitout, A, Cappai, M.N. Gangnerau, G. Reach, G. Brutzo. A technical alternative for a simple swine pancreas procurement for islet transplantation. *Cell Transplant* 1994, 3/3: 236.

35. V. Poitout, M. Armstrong, R.P. Robertson. G-protein-mediated somatostatin and epinephrine inhibition of glucose-induced insulin secretion from βTC6 cells. *Diabetologia* 1994, 37/Suppl.1: A32.

36. V. Poitout, M. Armstrong, R.P. Robertson. G-protein-mediated somatostatin and epinephrine inhibition of glucose-induced insulin secretion from βTC6 cells. *Clin Res* 1994, 42/3: 353.

37. V. Poitout, L. K. Olson and R. P. Robertson. Chronic exposure of ßTC-6 cells to high glucose concentrations paradoxically decreases insulin gene transcription. *J Investig Med* 1995, 43/Suppl 3: 481A.

38. V. Poitout, L. K. Olson, R. P. Robertson. Chronic exposure of ßTC-6 cells to supraphysiologic glucose concentrations decreases binding activity of the RIPE3b1 insulin gene transcription activator. *Horm Metab Res* 1996, 28: 44A.

39. V. Poitout, L. K. Olson , R. P. Robertson. Mécanismes de la diminution rapide et réversible de la transcription du gène de l'insuline de cellules INS-1 cultivées dans un milieu riche en glucose. *Diabete Metab* 1996, 22:V.

40. L. K. Olson , V. Poitout, R. P. Robertson. La culture chronique de cellules insulinosécrétrices ßTC-6 dans un milieu riche en glucose entraîne une diminution de l'activité du facteur de transcription agissant sur la séquence RIPE3b1 du gène de l'insuline. *Diabete Metab* 1996, 22:VI.

41. S. Darquy, V. Poitout, G. Reach. Isolement, culture et encapsulation d'îlots de Langerhans de porc pour la réalisation d'un pancréas bioartificiel. 5ème congrès de la Société de Pharmaco-toxicologie cellulaire. Bordeaux, March 1996.

42. L. K. Olson , V. Poitout, R. P. Robertson. Glucose rapidly and reversibly attenuates insulin gene transcription in INS-1 cells by decreasing STF-1 and RIPE3b1 binding activities. *Diabetes* 1996, 45/Suppl 2: 243 A.

43. Moran, H.J. Zhang, L.K. Olson, V. Poitout, R.P. Robertson. Differentiation of glucose toxicity from ß-cell exhaustion in the pancreatic ß-cell line, HIT-T15. *Diabetologia* 1996, 39/Suppl 1: A 129.

44. V. Gupta, D.M. Kendall, D.P. Rooney, V. Poitout, D.C. Wahoff, D.E.R. Sutherland, R.P. Robertson. The defective glucagon response from transplanted intrahepatic pancreatic islets during hypoglycemia is transplantation site-determined. *Diabetologia* 1996, 39/Suppl 1: A

45. D.M. Kendall, M.B. Armstrong, B. Hoppe, V. Poitout, L.K. Olson, R.L. Sorenson, R.P. Robertson. Functional and morphological characterization of the glucagon-secreting cell line, alphaTC1-9. *J Investig Med* 1997, 45/1: 165 A.

46. V. Poitout, C. Rouault, M. Guerre-Millo, I. Briaud, G. Reach. Effet inhibiteur de la leptine sur la sécrétion d'insuline en réponse au glucose dans l'îlot de Langerhans de rat isolé. *Diabete Metab* 1997, 23/Suppl. 1: XXVIII A.

47. V. Poitout, C. Rouault, M. Guerre-Millo, I. Briaud, G. Reach. Leptin inhibits glucose-induced insulin secretion from isolated rat islets of Langerhans. *Diabetes* 1997, 46/Suppl 1: 4A.

48. V. Poitout, C. Rouault, M. Guerre-Millo, G. Reach. La leptine inhibe la potentialisation de la sécrétion d'insuline par l'IBMX et le carbachol dans l'îlot de Langerhans de souris isolé. *Diabete Metab* 1998, 24/Suppl. 1: XVIII A.

49. A. Abderrahmani, M. Vaxillaire, C. Rouault, M. Pontoglio, G. Reach, M. Yaniv, P. Froguel, B. Bailleul, V. Poitout. La culture chronique de cellules insulinosécrétrices dans un milieu de forte concentration de glucose entraine une diminution de l'activité transcriptionnelle du facteur HNF-1. *Diabete Metab* 1998, 24/Suppl. 1: XVIII A.

50. I. Briaud, C. Rouault, G. Reach, V. Poitout. La culture d'îlots de Langerhans de rat pendant 6 semaines dans une forte concentration de glucose entraine une diminution de l'expression du gène de l'insuline. *Diabete Metab* 1998, 24/Suppl. 1: XXXVI A.

51. A. Abderrahmani, M. Vaxillaire, C. Rouault, M. Pontoglio, G. Reach, M. Yaniv, P. Froguel, B. Bailleul, V. Poitout. Chronic Exposure of HIT-T15 Cells to Supraphysiologic Glucose Concentrations Decreases Activity of the HNF-1 Transcription Factor Response Element. *Diabetes* 1998, 47/Suppl. 1: A48.

52. I. Briaud, C. Rouault, G. Reach, V. Poitout. Long-term Exposure of Isolated Islets to Supraphysiologic Glucose Concentrations Decreases Insulin Gene Expression. *Diabetes* 1998, 47/Suppl. 1: A250.

53. V. Poitout, C. Rouault, M. Guerre-Millo, G. Reach. Leptin Inhibits Potentiation of Glucose-Induced Insulin Secretion by Carbachol or IBMX in Isolated Mouse Islets. *Diabetes* 1998, 47/Suppl. 1: A411.

54. A. Abderrahmani, M. Vaxillaire, C. Rouault, M. Pontoglio, G. Reach, M. Yaniv, P. Froguel, B. Bailleul, V. Poitout. Chronic Exposure of HIT-T15 Cells to Supraphysiologic Glucose Concentrations Decreases Activity of the HNF-1 Transcription Factor Response Element. *Diabetologia* 1998, 41/Suppl. 1: A185.

55. V. Poitout, C. Rouault, J.C. Marie, M. Guerre-Millo, G. Reach. Leptin Inhibits Potentiation of Insulin Secretion in Mouse Islets without altering cytosolic Ca2+ levels. *Diabetologia* 1998, 41/Suppl. 1: A221.

56. S. Jacqueminet, C. Rouault, G. Reach, V. Poitout. Long-term exposure of isolated rat islets of Langerhans to palmitate partially prevents the stimulatory effect of glucose on insulin content and insulin mRNA levels. *J Investig Med* 1999, 47: 28A.

57. S. Jacqueminet, I. Briaud, C. Rouault, G. Reach, V. Poitout. Long-term exposure of isolated rat islets to palmitate inhibits insulin gene expression. *Diabetes* 1999, 48/Suppl 1: A242.

58. I. Briaud, C.L. Kelpe, J.S. Harmon, S.A. Metz, V. Poitout. Palmitate-induced impairment of insulin gene expression in pancreatic beta-cells is associated with intracellular accumulation of triacylglycerols. *J Investig Med* 2000, 48: A113.

59. P.O.T. Tran, C.E. Gleason, V. Poitout, R.P. Robertson. Sodium salicylate blocks interleukin-1ß-induced cyclooxygenase gene expression and inhibition of insulin secretion. *J Investig Med* 2000, 48: A113.

60. P.O.T. Tran, C. E. Gleason, V. Poitout, R. P. Robertson. Inhibition of cyclooxygenase-2 (COX-2) and type 3 prostaglandin E receptor (EP3) gene expression are mechanisms whereby sodium salicylate (SS) interferes with IL-1-β inhibition of insulin secretion. *Diabetes* 2000, 49/Suppl 1: A261.

61. I. Briaud, C. L. Kelpe, P.O.T. Tran, V. Poitout. High-fat diet impairs beta-cell function in Goto-Kakizaki rats independently of lipotoxicity. *Diabetes* 2000, 49/Suppl 1: A262.

62. J. S. Harmon, I. Briaud, R. P. Robertson, V. Poitout. An improved method for measurement of triacylglycerol content in pancreatic islets. *Diabetes* 2000, 49/Suppl 1: A263

63. I. Briaud, C. L. Kelpe, J. S. Harmon, S. A. Metz, V. Poitout. Palmitate inhibition of glucose-induced insulin gene expression is associated with increased intracellular accumulation of neutral lipids in pancreatic beta-cells. *Diabetes* 2000, 49/Suppl 1: A415.

64. J.S. Harmon, C.E. Gleason, Y. Tanaka, V. Poitout, R.P. Robertson. Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene expression in Zucker Diabetic Fatty rats. *Diabetes* 2001, 50/Suppl 2: A319.

65. I. Briaud, C.L. Kelpe, L.M. Johnson, P.O.T. Tran, V. Poitout. Differential effects of hyperlipidemia on insulin secretion in islets of Langerhans from hyperglycemic vs. normoglycemic rats. Western Islet Club, San Francisco, CA, September 2001.

66. I. Briaud, C.L. Kelpe, L.M. Johnson, P.O.T. Tran, V. Poitout. Differential effects of hyperlipidemia on insulin secretion in islets of Langerhans from hyperglycemic vs. normoglycemic rats. . Beta-cell biology for the 21st century. National Institutes of Health, Bethesda, MD, November 2001.

67. M. Prentki, R. Roduit, C. Alarcon, S.P. Wang, P. Masiello, V. Poitout, C.J. Rhodes, G. Mitchell. Metabolic signals for insulin secretion. Beta-cell biology for the 21st century. National Institutes of Health, Bethesda, MD, November 2001.

68. R. Roduit, C. Alarcon, F. Massé, C.L. Kelpe, V. Poitout, C.J. Rhodes, M. Prentki,. Overexpressing malonyl-CoA decarboxylase in the cytosol alters lipid partitioning and glucose-induced insulin secretion in pancreatic beta-cells. Beta-cell biology for the 21st century. National Institutes of Health, Bethesda, MD, November 2001.

69. V. Poitout, C.L. Kelpe, L. Johnson. Overexpression of Diacylglycerol-Acyltransferase inhibits glucose-induced insulin secretion in isolated rat islets of Langerhans. *Diabetes* 2002, 51/Suppl 2: A1.

70. K. Yaekura, R. Julyan, B.L. Wicksteed, L.B. Hays, C. Alarcon, D. Baskin, V. Poitout, L.H. Philipson, C.J. Rhodes. Rab3A Null Mice Develop a Pancreatic β-cell Defect Glucose Intolerance due to an Insulin Exocytotic Defect. *Diabetes* 2002, 51/Suppl 2: A72.

71. S. Matsumoto, S. Qualley , S. Goel , D. Hagman, Ian R. Sweet, V. Poitout , D. M. Strong, R. P. Robertson, J. Reems. The effect of the two-layer [University of Wisconsin solution (UW) / Perfluorochemical+ O_2] method on human islet isolation as assessed by the Edmonton isolation protocol. American Transplant Meeting 2002.

72. H. Bihan, C. Rouault, M. Guerre-Millo, V. Poitout, B. Staels, G. Reach. Rôle de PPARα dans l'insulino-sécrétion: Étude fonctionnelle des îlots de Langerhans de souris invalidées pour PPARα. ALFEDIAM 2003.

73. C.L. Kelpe, C.S. Sutton, P.C. Moore, B. Wicksteed, C.J. Rhodes, V. Poitout. Fatty acids inhibit insulin gene transcription in isolated rat islets of Langerhans. Keystone symposium "Towards understanding islet biology" 2003.

74. C.L. Kelpe, P.C. Moore, C.S. Sutton, Susan D. Parazzoli, B. Wicksteed, C.J. Rhodes, V. Poitout. Palmitate inhibition of insulin gene expression in isolated rat islets is transcriptional and mediated by de novo ceramide synthesis. *Diabetes* 2003, 52/Suppl 1: A377.

75. M. Prentki, C. Nolan, C. Alarcon, C. Kelpe, E. Przybykowski, J. Morin, F. Masse, N. Ruderman, C. Rhodes, V. Poitout, R. Roduit. A role for malonyl-CoA and lipid signaling in the regulation of insulin secretion in response to both fuel and non-fuel stimuli. *Diabetes* 2003, 52/Suppl 1: A383.

76. V. Poitout, P.C. Moore, C.S. Sutton, S.D. Parazzoli, B. Wicksteed, C.J. Rhodes, C.L. Kelpe. Mechanisms of fatty acid inhibition of insulin gene expression in isolated rat islets. *Diabetologia* 2003, 46/Suppl 2: A 177.

77. D.K. Hagman, M.A. Ugas, P.C. Moore, S.D. Parazzoli, V. Poitout. Fatty-acid inhibition of insulin secretion: In search of a mechanism. Western Region Islet Study Group Meeting, Seattle, WA, September 2003.

78. M.A. Ugas, P.C. Moore, V. Poitout. Fatty-acid inhibition of insulin secretion: In search of a mechanism. National Conferences on Undegraduate Research, Indianapolis, IN, April 2004.

79. D.K. Hagman, S.D. Parazzoli, V. Poitout. Prolonged exposure to palmitate reduces PDX-1 and MafA binding to the insulin gene promoter. Western Region Islet Study Group Meeting, Catalina Island, CA, October 2004.

80. D.K.Hagman, S.D. Parazzoli, V. Poitout. Prolonged exposure of isolated rat islets to palmitate reduces PDX-1 and MafA binding to the insulin gene promoter. Keystone Symposium: Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies, Keystone, CO, January 2005.

81. D.K. Hagman, S.D. Parazzoli, V. Poitout. Prolonged Exposure of Isolated Rat Islets to Palmitate Reduces PDX-1 and MafA Binding to the Insulin Gene Promoter. Diabetes 2005, 54/Suppl 1: A399.

82. P.C. Moore, D.C. Lin, J. Luo, V. Poitout. Deletion of the GPR40 gene impairs fatty-acid potentiation of insulin secretion in isolated mouse islets. Diabetes 2005, 54/Suppl 1: A83.

83. T. Alquier, M.G. Latour, E. Oseid, D. Lin, J. Luo, V. Poitout. Role of GPR40 in fatty-acid modulation of insulin secretion. Imaging the Pancreatic Beta Cell in Health and Disease, 3rd Workshop, Washington, DC, April 2006.

84. G. Fontes, D.K. Hagman, J. Rutter, V. Poitout. Palmitate activates Akt and ERK1/2 phopshorylation and decreases PAS kinase expression in pancreatic beta-cells. Diabetes 2006, 55/Suppl 1 : A80.

85. M.G. Latour, E. Oseid, T. Alquier, T.L. Jetton, J. Juo, D.C.H. Lin, V. Poitout. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion. Boston-Ithaca Islet Club, Boston, IL, November 2006. .

86. T. Alquier, M.G. Latour, E. Oseid, C. Tremblay, T.L. Jetton, J. Luo, DC-H Lin, V. Poitout. GPR40 is necessary but not sufficient for fatty-acid stimulation of insulin secretion in vivo. Translating Islet Biology into Diabetes Therapy Research Symposium, American Diabetes Association, Stone Mountain, Georgia, March 2007.

87. D.K. Hagman, M.G. Latour, S.K. Chakrabarti, G. Fontes, J. Amyot, C. Tremblay, M. Semache, J.A. Lausier, V. Roskens, R.G. Mirmira, T.L. Jetton, V. Poitout. Cyclical and alternating infusions of glucose and intralipid in rats inhibit insulin gene expression and Pdx-1 binding in islets. Boston-Ithaca Islet Club, Boston, IL, October 2007

88. V. Poitout Glucolipotoxicity of the pancreatic Beta-Cell. European Journal of Clinical Investigation 2008, 38/Suppl 1 A406.

89. G. Fontes, M. Semache, C. Trembaly, J. Rutter, V. Poitout. PAS Kinase Mediates Palmitate Inhibition of Insulin Gene Expression in Pancreatic Beta-Cells, Islet and Beta Cell Biology, Snowbird Utah, April 2008

90. A. Kooli, J-C. Honoré, T. Alquier, X. Hou, V. Poitout, M. Balazy and S. Chemtob. Trans-arachidonic acids induce microvascular degeneration via early activation of GPR40. Pediatric Academic Societies and Asian Society for Pediatric Research Joint meeting. 2-6 May 2008 - Honolulu, Hawaii, USA.

91. A. Kooli, J-C. Honoré, T. Alquier, X. Hou, V. Poitout, M. Balazy and S. Chemtob. Trans-arachidonic acids induce microvascular degeneration via early activation of GPR40. 10th International conference of Eicosanoids and Bioactive Lipids in Cancer, Inflammation and related diseases. 16-19 September 2008, Montréal, Québec, Canada.

92. G. Fontes, M. Semache, C. Tremblay, J. Rutter, V. Poitout. Palmitate inthibition of insulin gene expression is mediated by PAS Kinase in Pancreatic Beta-Cells. Diabetes 2008, 57/Supp 1 : A79

93. M. Kebede, T. Alquier, M.G. Latour, M. Semache, V. Poitout. GPR40 Knock-Out mice are more susceptible to high fat diet-induced diabetes. Diabetes 2008, 57/Supp 1 : A462

94. T. Alquier, M. Kebede, S. Gesta, C.M. Sorensen, M-L. Peyot, R.J. Moore, R.C. Kahn, M. Prentki, T.O. Metz, V. Poitout, Global Transcriptomic and Metabolomic Profiling of GPR40 Knock-Out Mouse Islets. Canadian Journal of Diabetes, December 2008

95. G. Fontés, M. Semache, D.K. Hagman, J. Rutter, V. Poitout, PAS Kinase Mediates Palmitate Inhibition of Insulin Gene Expression in Pancreatic Beta-cells. CDA/CSEM Professional Conference and Annual Meetings, Montreal (Qc), Canada, October 2008

96. M. Kebede, T. Alquier, M.G. Latour, M. Semache and V. Poitout, The Fatty-Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo After High-Fat Feeding. CDA/CSEM Professional Conference and Annual Meetings, Montreal (Qc), Canada, October 2008

97. J. Amyot, D.K. Hagman, G. Fontés and V. Poitout, A Role for ER Stress and JNK in Fatty Acid Inhibition of the Insulin Gene. CDA/CSEM Professional Conference and Annual Meetings, Montreal, Qc, Canada, October 2008

98. J-C. Honoré, A. Kooli, T. Alquier, K. Jain, V. Poitout, M. Balazy, S. Chemtob. Trans-arachidonic acids generated after nitrative stress induce cerebral microvascular degeneration through activation of the GPR40 receptor, Free Radical Biology & Medicine, 2008, 45/Supp 1: S145.

99. J. Amyot, D.K. Hagman, G. Fontés and V. Poitout. The roles of inflammation and the unfolded protein response in glucolipotoxicity of the insulin gene, Boston-Ithaca Islet Club, Ithaca, NY, Novembre 2008

100. T. Alquier, M-L. Peyot, M.G. Latour, M. Kebede, C.M. Sorensen, S. Gesta, C. Kahn, R.D. Smith, T.L. Jetton, T.O. Metz, M. Prentki, V. Poitout. Roles of GPR40 in insulin secretion and islet intracellular metabolism, -Ithaca Islet Club, Ithaca, NY, Novembre 2008

101. T. Alquier, M-L. Peyot, M.G. Latour, M. Kebede, C.M. Sorensen, S. Gesta, C. Kahn, R.D. Smith, T.L. Jetton, T.O. Metz, M. Prentki, V. Poitout. The Fatty-Acid Receptor GPR40 regulates insulin secretion in islets. Keystone Symposia, Type 2 Diabetes and Insulin Resistance, Banff (AB), Canada, January 2009

102. F. Wauquier, T. Alquier, V. Poitout, P. Pilet, J. Guicheux, V. Coxam, Y. Wittrant. Implication des récepteurs aux acides ras dans les mécanismes du remodelage osseux. Oral, Journées françaises de biologie des tissus minéralisés, Mars 2009.

103. B. Zarrouki, D.K. Hagman, G. Fontés, M.G. Latour, M. Semache, M. Prentki, V. Poitout. Effects of simultaneous infusion of glucose and intralipid on beta-cell function in rats. Boston Ithaca Islet Club Meeting, Sturbridge, MA, May 2009.

104. M. Kebede, T. Alquier, V. Poitout. Regulation of GPR40 gene expression. Boston Ithaca Islet Club Meeting, Sturbridge, MA, May 2009.

105. M. Kebede, T. Alquier, R. Kulkarni, M. Walker, V. Poitout. Regulation of GPR40 gene expression. Recent Advances in Beta Cell Biology: Scientific and Clinical Implications, Toronto, October 2009.

106. J. Amyot, D. K. Hagman, E. Joly, V. Poitout. Activating Tanscription Factor 6 (ATF6): A novel transcriptional regulator of the insulin gene? Recent Advances in Beta Cell Biology: Scientific and Clinical Implications, Toronto, October 2009.

107. M. Semache, G. Fontés, J. Rutter, V. Poitout. The role of PAS Kinase in the regulation of insulin gene expression. Recent Advances in Beta Cell Biology: Scientific and Clinical Implications, Toronto, October 2009.

108. B. Zarrouki, G. Fontés, D. K. Hagman, M. G. Latour, M. Semache, V. Roskens, M. Prentki, T. L. Jetton, V. Poitout. Nutrient excess age-dependently impairs beta-cell function in rats despite a marked increase in beta-cell mass. Recent Advances in Beta Cell Biology: Scientific and Clinical Implications, Toronto, October 2009.

Dissertations

1. Le chien comme modèle expérimental dans l'évaluation d'un capteur de glucose. Mémoire présenté pour l'obtention du Diplôme d'Études Approfondies d'Endocrinologie. Université Pierre et Marie Curie. September 1990.

2. Les dysendocrinies à expression cutanée du chat: étude bibliographique. Thèse de Doctorat Vétérinaire. Université de Créteil. September 1991.

3. Développement d'un système d'autosurveillance continue de la glycémie chez l'homme. Mise au point de méthodes expérimentales et cliniques d'évaluation. Thèse de Doctorat de l'Université Paris 6. June 1993.

4. Modulation de la fonction pancréatique par les acides gras. Mémoire d'habilitation à diriger les recherches. Université Pierre et Marie Curie. May 2006.

Educational Publications

1. Commentary of 2 articles in G. Slama, ed. "Éditions de l'année en diabétologie 2001 » Eska, Paris 2002.

2. Commentary of 3 articles in G. Slama, ed. "Éditions de l'année en diabétologie 2003 » Eska, Paris 2004.

3. Commentary of 2 articles in G. Slama, ed. “Éditions de l’année en diabétologie 2005 » Eska, Paris 2005.
4. De l’insulinorésistance au diabète de type 2 : la réponse de la cellule bêta. Médecine Clinique – Endocrinologie et Diabète 2005, Hors-série 42-46.
5. Commentary of 2 articles in G. Slama, ed. “Éditions de l’année en diabétologie 2006 » Eska, Paris 2006.
6. Vers de nouveaux traitements du diabète, « Le guide des Tendances 2009 », Québec 2009, 73-74.